Semagacestat
5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
5
Ongoing
0
Recruiting
0
Completed
5
Sites
252
Countries
31
Endpoints
156
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 156 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 78 of 156 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
36
12
10
10
10
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
5 of 5
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00594568Effect of LY450139 on the Long Term Progression of Alzheimer's Disease | Semagacestat Alzheimer’s disease | mild-to-moderate AD | Ph 3 | Completed | 148 | May 2011 | 4 | results |
| IDENTITY-2Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo | Semagacestat Alzheimer’s disease | mild-to-moderate AD | Ph 3 | Completed | 91 | Apr 2011 | 2 | results |
| Identity XTA Study of Semagacestat for Alzheimer's Patients | Semagacestat Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 71 | Apr 2011 | - | results |
| NCT00244322Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease | Semagacestat Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 6 | Dec 2006 | 2 | |
| NCT00765115A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response. | Semagacestat Alzheimer’s disease | Healthy volunteers | Ph 1 | Completed | 1 | Sep 2007 | 1 |
Showing 1-5 of 5 trials